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Abstract
Background: Persistent endobronchial inflammation is in part responsible for the attrition of lung function seen in cystic
fibrosis. Leukotrienes act as pro-inflammatory mediators. The aim of this study was to assess the efficacy of the leukotriene
receptor antagonist zafirlukast as a potential anti-inflammatory agent in the treatment of adult patients with cystic fibrosis.
Methods: Clinically stable patients were enrolled in the study if they had no history or clinical evidence of asthma, bronchial
hyper-reactivity, or aspergillosis. They were randomised to receive zafirlukast 20 mg twice daily with all routine treatment for
four months or routine treatment alone in an open cross-over design. Primary endpoints were changes in respiratory function tests
and a modified NIH clinical score. Results: Thirty patients were enrolled and 25 completed. There was a significant improvement
in the modified NIH clinical score but no significant increase in respiratory function with zafirlukast. Conclusions: Patients
receiving a leukotriene receptor antagonist in addition to routine treatments showed significant improvement in a clinical score
which is a composite of clinical wellbeing, chest radiograph appearance, and physical examination. Respiratory function showed
a non-significant trend towards improvement with treatment. Zafirlukast may benefit patients with CF. An adequately powered
study is justified on the basis of these results.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Leukotrienes (LTs) are formed from activated inflam-
matory cells. These proinflammatory chemical mediators
recruit other inflammatory cells to lung tissue and in
the airways stimulate mucus hypersecretion, oedema and
bronchospasm w1x. The C4, D4, and E4 LTs, referred to
as the cysteinyl-LTs as each has a thio-ether linked
peptide, all use the CysLT airway receptor site. Zafir-1
lukast acts as a LT receptor antagonist, interrupting the
inflammatory cascade by preventing the cysteinyl-LTs
activating the receptor. Randomised, double-blind, pla-
cebo-controlled trials have shown significant improve-
ments in asthma symptoms and lung function following
treatment with zafirlukast 20 mg twice daily w2,3x.
The important negative effect of uncontrolled inflam-
mation on lung function in cystic fibrosis (CF) is well
documented w4,5x. The pathogenic potential of LTs in
CF has been suggested by several studies. Sampson et
al. w6x showed that children with CF had greater urinary
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LTE4 levels than controls. Urine levels correlated sig-
nificantly with sputum LTE4 levels and with the total
cysteinyl-LT content in sputum. High levels of both
LTE4 and LTB4 were found in sputum. Spencer et al.
w7x documented high sputum cysteinyl-LT levels, which
correlated with the overall severity of the pulmonary
disease in children. Greally et al. w8x showed a signifi-
cant positive correlation between TNF-alpha and both
LTB4 and total cysteinyl-LT sputum content. Respiratory
function was inversely related to TNF-alpha concentra-
tions, suggesting that both LTs and TNF-alpha may be
involved in airway inflammation and obstruction in CF.
These studies suggest a role for LTs in the pathophy-
siology of CF.
There are only two studies on the use of LT receptor
antagonists in CF. Morice et al. w9x gave montelukast to
11 stable but otherwise unselected patients with CF for
2 weeks in an open label trial. Patients documented
subjective improvement and better exercise tolerance.
Schmitt-Grohe et al. w10x gave montelukast or placebo
to 16 patients with CF for 21 days each in a cross-over
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Table 1
Mean values (S.D.) of baseline assessments for primary outcome variables
Number FEV1(l) FEV1 FVC(l) FVC FEF (l)25–75 FEF25–75 Modified
(%pred) (%pred) (%pred) NIH score
(0–50)
Group 1 11 2.25 59 3.3 75.5 1.47 31.1 20.5
Zafirlukast (1.03) (20.8) (1.2) (20.6) (0.99) (18.8) (7.4)
Period 1
Group 2 14 2.45 64.4 3.54 79.9 1.99 43.9 18.8
Zafirlukast (1.01) (24.4) (0.93) (19.4) (1.87) (38.6) (6.7)
Period 2
Table 2
Mean values (S.D.) of baseline assessment for secondary outcome variables
Number Weight Crp Plasma White IgG Dyspnoea General CF symptom
(kg) (mgyl) viscosity cell count (gyl) score wellbeing score score
(cP) (=10 yl)9 (mm) (0–25) (0–25)
Group 1 11 60 12.6 1.81 12.1 14.8 23.4 20 17.5
Zafirlukast (10.5) (6.6) (0.09) (4.9) (3.7) (16.5) (4.3) (3.4)
Period 1
Group 2 14 60.8 14.3 1.8 10.2 13.9 13.8 22.6 20.5
Zafirlukast (8.9) (14.8) (0.19) (2.9) (3.4) (13.1) (3) (2.1)
Period 2
study. They found a significant reduction in serum
eosinophilic cationic protein and in eosinophils, sug-
gesting that blocking of the LT receptor might reduce
eosinophilic inflammation.
The aim of this study was to see if the anti-inflam-
matory effects of zafirlukast resulted in improvements
in lung function and clinical wellbeing in adult patients
with CF who had no evidence of bronchial hyper-
reactivity or allergic bronchopulmonary aspergillosis
(ABPA).
2. Patients and methods
Clinically stable patients were invited to participate
in the study. Exclusion criteria were any of the follow-
ing; history of recent ABPA or asthma, bronchodilator
reversibility )15%, raised peripheral blood eosinophil
count, serum IgE)200 IU, or positive aspergillus RAST
or precipitin test results. Patients were randomised to
receive zafirlukast 20 mg twice daily plus all routine
treatments for 4 months followed by routine treatment
alone for 4 months, or vice versa, in an open-label
cross-over trial. A washout period was not introduced
between the two arms of the study as only data from
the end of each treatment period were analysed, except
for days of additional antibiotic therapy (a secondary
outcome variable).
Patients received the following concomitant respira-
tory directed therapies; nebulised antibiotics 55%, bron-
chodilators 93%, oral corticosteroids 21%, inhaled
corticosteroids 66%, pulmozyme 52%.
Outcome measures were recorded at baseline and at
2 monthly intervals to 8 months. These included respi-
ratory function tests (RFTs), weight, and peripheral
blood inflammatory markers (c reactive protein, white
cell count, IgG, plasma viscosity). Four clinical scores
were completed, modified from Ranasinha et al. w11x
Dyspnoea was represented by a 100 mm vertical line
ranging from no shortness of breath at the bottom to
severe shortness of breath at the top w12x. Patients scored
the line according to perceived dyspnoea experienced.
Answers to questions on general well being (feeling,
energy, physical activity, appetite and sleep pattern) and
on CF related symptoms (ease of sputum expectoration,
cough frequency and severity, congestion, wheeze) were
ranked on a 5-point Likert scale in which one repre-
sented the worst symptoms and five represented no
symptoms. Finally a modified NIH score (details avail-
able on request) was used to assess overall clinical
status w13x at 0, 4 and 8 months. At each visit patients
were asked to report the number of days on which
additional oral or intravenous antibiotics had been
prescribed.
Primary outcome measures were changes in RFTs,
absolute values and percent predicted, and the modified
NIH clinical score. The data were analysed according to
the methods of Hills and Armitage for cross-over studies
w14x. T-tests were applied to test for treatment by period
interactions, period effects and treatment effects. For all
variables except days of additional antibiotic therapy the
data recorded at 4 and 8 months were used in the
analysis as the assessments of response in the first and
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Fig. 1. Mean responses (S.E.) in each treatment arm for primary outcome variables.
Table 3
Mean responses (S.D.) and treatment effects in each treatment arm for secondary outcome variables
Number Wt. Intra-venous Oral CRP Plasma White cell IgG Dyspnoe General well- CF
(kg) anti-biotics anti-biotics (mgyl) viscosity count (gyl) score being score symptom score
(days) (days) (cP) (=10 yl)9 (mm) (0–25) (0–25)
Mean responses
Zafirlukast 25 60.8 12.8 6.9 14.4 1.78 10.5 13.8 18.8 21.6 19.3
(9.5) (12.9) (8.9) (16.8) (0.14) (4.2) (3.6) (19.5) (2.8) (3.2)
No treatment 25 61 12.4 5 15.4 1.81 9.5 14.3 25.3 20.6 17.9
(9.6) (15.1) (8.3) (15.8) (0.16) (3.4) (3.3) (24.8) (4.4) (4.1)
Treatment effect
Effect size 0.14 y0.19 1.27 y2.01 y0.03 0.73 – y6.62 0.99 1.32
0.55
95% CI 0.9 y6.44 y2.08 y9.74 y0.08 y1.21 – y14.9 y0.98 y0.43
0.62 6.07 4.61 5.71 0.02 2.66 y1.17 1.67 2.95
0.07
P value 0.69 0.95 0.4 0.6 0.26 0.44 0.08 0.11 0.3 0.13
second treatment periods respectively. For days of added
intravenous and oral antibiotic therapy, responses during
the first and second periods were denoted respectively,
by the sum of the data recorded at 2 and 4 months, and
at 6 and 8 months. In all tests a P-value -0.05 denoted
statistical significance.
3. Results
Thirty patients, (15 male), were entered into the
study. Mean patient age was 24 years (range 20–32
years). Due to the cross-over design all patients were
required to have had at least one assessment of efficacy
for both treatment periods to be eligible for analysis.
Consequently five patients (two receiving zafirlukast in
the first period) were excluded as they withdrew before
the start of the second treatment period. The withdrawals
were not related to any adverse event or drug side effect.
Eleven of the remaining 25 received zafirlukast in the
first treatment period.
The baseline data are summarised in Tables 1 and 2.
Mean responses for primary outcome variables are
shown in Fig. 1. Mean responses and treatment effects
for secondary outcome variables are shown in Table 3.
There was no evidence of a significant treatment by
period interaction for any variable and therefore the
cross-over methods could be applied to all variables.
With respect to the primary variables, the modified
NIH score was significantly lower on zafirlukast com-
pared to routine treatment, (estimated treatment effect
y1.57, P-0.05). Both absolute and percent predicted
values for FEV1 and FVC were non-significantly higher
on zafirlukast, (effect size 0.04 l, 0.81% and 0.04 l,
0.91%, respectively). FEF values showed a signif-25–75%
icant period effect (Ps0.01) and tended to be higher
in the first treatment period irrespective of which treat-
ment the patient was receiving. Consequently the esti-
mates of the treatment effects for FEF are not25–75%
reliable as it is impossible to separate out the true
treatment effect from the period effect.
With respect to the secondary outcome measures there
was no evidence of a significant difference between
zafirlukast and routine treatment for any of the variables.
Significant period effects were apparent for c-reactive
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protein (Ps0.04) and total peripheral blood white cell
count (Ps0.02), with both variables tending to be
lower in period one. The treatment effects associated
with them should therefore be interpreted with caution.
No adverse events were reported.
4. Discussion
In adult patients with CF, who were selected to
minimise any benefits that might be derived from its
efficacy as an asthma drug, the addition of the LT
receptor antagonist zafirlukast to routine treatment regi-
mens significantly improved patients’ clinical status as
measured by a modified NIH score. There were non-
significant improvements in respiratory function, plasma
viscosity, IgG levels, dyspnoea, wellbeing and CF symp-
tom scores, and fewer days of intravenous therapy.
Twenty-five patients completed the trial and greater
differences between treatment with and without zafirlu-
kast may be evident in a larger multicentre study.
Morice et al. w9x attributed the efficacy of a LT
receptor antagonist in CF to a blockage of the effects
of Aspergillus stimulated Th2 inflammation and LT
synthesis. In our study we excluded patients with evi-
dence of immunological reactivity to Aspergillus infec-
tion as well as those with significant bronchial
reversibility. We suggest that any benefit from the LT
receptor antagonists in clinically stable patients with CF
is a reflection of their interference with the persistent
lower respiratory tract inflammation that characterises
this disease. This hypothesis is supported by Schmitt-
Grohe et al. who presented data at the 24th European
CF Conference 2001 which showed a montelukast
induced fall in eosinophilic inflammation w10x.
LTB4 may be important in mediating neutrophil influx
and activation, hence encouraging the neutrophil domi-
nated inflammation in the CF lung w15,16x. Zafirlukast
does not block the LTB4 receptor. Treatment that inter-
feres with the action of LTB4 as well as the cysteinyl-
LTs, for example 5-lipoxygenase inhibitors that block
LT production from eicosanoids, might further benefit
patients.
Our data suggest that treatment with zafirlukast may
benefit patients when they are assessed by a clinical
score which includes chest radiograph appearance, phys-
ical examination, presence or not of haemoptysis, spu-
tum characteristics, and general health measures such as
appetite, energy, exercise tolerance and dyspnoea. Plas-
ma viscosity, serum IgG, and a dyspnoea score were
also lower with treatment, and respiratory function,
general well-being and CF symptom scores better. When
receiving zafirlukast patients needed less days of intra-
venous antibiotic therapy. However, the differences
between treatments only reached statistical significance
for the modified NIH clinical score.
In conclusion, we have shown that the LT receptor
antagonist, zafirlukast, results in a measurable clinical
improvement in adult patients with CF and appears to
be well tolerated. We suggest that there is now sufficient
data to warrant evaluation of the role of LT antagonists
in CF in an adequately powered clinical trial.
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